When is off-label off-road?

Affiliations

¹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: e.g.e.de.vries@umcg.nl.
² Department of Medical Oncology, Cancer Pain and Palliative Medicine Service, Shaare Zedek Medical Center, Jerusalem, Israel.
³ Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Amsterdam, The Netherlands.

Editorial

E G E de Vries et al. Ann Oncol. 2019.

. 2019 Oct 1;30(10):1536-1538.

doi: 10.1093/annonc/mdz445.

¹ Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. Electronic address: e.g.e.de.vries@umcg.nl.
² Department of Medical Oncology, Cancer Pain and Palliative Medicine Service, Shaare Zedek Medical Center, Jerusalem, Israel.
³ Division of Molecular Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands; Oncode Institute, Amsterdam, The Netherlands.

Erratum in

When is off-label off-road?
de Vries EGE, Cherny NI, Voest EE. de Vries EGE, et al. Ann Oncol. 2019 Dec 1;30(12):2018. doi: 10.1093/annonc/mdz455. Ann Oncol. 2019. PMID: 31893487 Free PMC article. No abstract available.

No abstract available

1. https://www.fda.gov/regulatory-information/search-fda-guidance-documents... (12 August 2019, date last accessed).
1. Kalis JA, Pence SJ, Mancini RS. et al. Prevalence of off-label use of oral oncolytics at a community cancer center. J Oncol Pract 2015; 11(2): e139–e143. - PubMed
1. Conti RM, Bernstein AC, Villaflor VM. et al. Prevalence of off-label use and spending in 2010 among patent-protected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol 2013; 31(9): 1134–1139. - PMC - PubMed
1. Wagner J, Marquart J, Ruby J. et al. Frequency and level of evidence used in recommendations by the National Comprehensive Cancer Network guidelines beyond approvals of the US Food and Drug Administration: retrospective observational study. BMJ 2018; 360: k668. - PMC - PubMed
1. Kurzrock R, Gurski LA, Carlson RW. et al. Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Ann Oncol 2019; 30(10): 1647–1652. - PMC - PubMed